Short answer: No peptide is FDA approved to speed up injury recovery. BPC-157 has dozens of animal studies but only tiny human reports: a 2025 systematic review found 35 preclinical studies and 1 clinical study. FDA found no human studies of TB-500 at all. Thymosin beta-4 and LL-37 have small human trials, but for dry eye and leg ulcers, not sports injuries.
| Compound | Best evidence | What it shows |
|---|---|---|
| BPC-157 | Small or early human studies | Rat studies show better tendon, ligament, muscle and bone healing. Human data is a 17-patient knee chart review, a 12-patient bladder study and a 2-person IV safety pilot, none with a control group. |
| TB-500 | No published studies found | TB-500 is a 7-amino-acid fragment. FDA reported in 2026 that it found no clinical studies of TB-500 in humans by any route. |
| Thymosin beta-4 (full-length protein) | Small or early human studies | A different, larger molecule than TB-500. A phase 1 trial gave it into a vein to healthy volunteers without serious side effects, and a 9-patient eye-drop trial tested it for severe dry eye. |
| GHK-Cu | Animal or lab studies only | Speeds wound healing in rats, mice, pigs and dogs. Human data is mostly small trials of face creams, not injuries. |
| LL-37 (topical) | Human trials | Tested as a wound gel for venous leg ulcers. A 34-person trial looked promising, but a 148-person phase 2b trial found no healing benefit overall. |
"Animal or lab studies only" means no published human trial for this goal that we could find. Results in rats or cells often do not carry over to people. Compounds that are not FDA-approved have no tested label for dose, purity or safety.
BPC-157 is a 15-amino-acid peptide based on a fragment of a protein in stomach juice. A 2025 systematic review in HSS Journal screened 544 articles and kept 36: 35 were preclinical (animal or lab) and 1 was clinical. In animals, it improved healing in muscle, tendon, ligament and bone injuries. The authors called the evidence level IV and V, the lowest grades, and found no clinical safety data.
The human reports we could find:
Real trials are starting. A placebo-controlled phase 2 trial of BPC-157 for hamstring strains began recruiting in China in 2026, and a 20-patient pilot after rotator cuff surgery is registered to start in 2027. No results are posted yet.
Most claims about TB-500 come from research on thymosin beta-4, a 43-amino-acid protein found in most cells. TB-500 is a short synthetic fragment of it. In its 2026 review, FDA wrote that the nomination cited three references, all on thymosin beta-4, and that FDA itself found no clinical studies of TB-500 in humans. FDA also found no human pharmacokinetic data (how the body absorbs and clears it) for any route.
The human data on full-length thymosin beta-4 is small and not about injuries: a phase 1 safety trial with 54 single-dose and 30 multiple-dose healthy volunteers given it into a vein, and a 9-patient phase 2 eye-drop trial for severe dry eye. Pairing it with BPC-157 is common; see BPC-157 vs TB-500 and the BPC-157 and TB-500 blend.
FDA keeps a page of bulk substances for compounding that may present significant safety risks. As of April 22, 2026, BPC-157, TB-500, GHK-Cu (injectable) and LL-37 appear in its table of substances that were previously in category 2 and whose nominations were withdrawn. The safety notes stay on the page: for BPC-157, possible immunogenicity (the body making an immune response against it), peptide impurities, and too little information to know whether it causes harm in people.
FDA then reviewed BPC-157 and TB-500 on its own for the 503A bulks list, which governs what state-licensed pharmacies may compound. In the July 2026 advisory committee materials, FDA proposed that neither be added. The committee only advises; FDA says it will make a final decision after weighing its input. See 503A vs 503B.
A 2025 review also notes BPC-157 is banned in professional sports.
Terms on this page: Peptide · Blend (peptide blend) · Research use only (RUO) · 503A vs 503B · Injection site rotation